Augmented efficacy of exogenous extracellular vesicles targeted to injured kidneys

作     者：Xiao-Jun Chen Kai Jiang Christopher M.Ferguson Hui Tang Xiangyang Zhu Amir Lerman Lilach O.Lerman Xiao-Jun Chen;Kai Jiang;Christopher M.Ferguson;Hui Tang;Xiangyang Zhu;Amir Lerman;Lilach O.Lerman

作者机构：Division of Nephrology and HypertensionMayo ClinicRochesterMNUSA Department of NephrologyThe Second Xiangya Hospital of Central South UniversityChangshaHunanChina Department of Cardiovascular DiseasesMayo ClinicRochesterMNUSA 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：817-819页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

基　　金：supported by NIH Grants Numbers DK122734 DK102325 and DK120292 

主　　题：kidney retention sized 

摘      要：Dear Editor,Extracellular vesicles(EVs)derived from mesenchymal stem/stromal cells(MSCs)contain genetic and protein material that stimulate tissue repair and ameliorate injury in recipient *** of particulate MSC-EVs over MSCs in treating kidney disease include better penetration of injured glomerular filtration barrier to access podocytes or tubular ***,systemic EV delivery yields low kidney retention efficiency,limiting their regenerative benefits.1 Previously,we coated adipose tissue-derived(AD)-MSC with antibodies against kidney injury molecule(KIM)‐1(ab-KIM1),a protein upregulated in damaged kidneys.2 Conjugating ab-KIM1 did not impair MSC function but increased their retention and reparative potency in murine renal artery stenosis(RAS).2 We hypothesized that ab-KIM1 conjugation would similarly enhance retention of exogenously delivered EVs in ischemic kidneys and confer superior therapeutic benefits.